Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317377 | 0.94 | LMNA (0.48) | RAB9AALDH1A1LMNAGAANPSR1 | |
| SCHEMBL6317733 | 0.93 | RAB9A (0.45) | RAB9AALDH1A1POLBLMNA | |
| SCHEMBL6318314 | 0.92 | TACR1 (0.45) | TACR1ALDH1A1POLBGAAHPGD | |
| SCHEMBL6324730 | 0.90 | HPGD (0.46) | RAB9AALDH1A1POLBLMNAGAA | |
| SCHEMBL6316611 | 0.88 | RAB9A (0.48) | RAB9AALDH1A1POLBLMNAGAA | |
| SCHEMBL6317335 | 0.87 | MLYCD (0.46) | ALDH1A1POLBLMNAGAAHPGD | |
| SCHEMBL6324233 | 0.86 | CA1 (0.50) | TACR1P2RX1TMPRSS4POLBLMNA | |
| SCHEMBL6318549 | 0.86 | RAB9A (0.46) | RAB9AALDH1A1POLBGAA | |
| SCHEMBL6316606 | 0.85 | HTR2C (0.44) | RAB9AALDH1A1POLBLMNANPSR1 | |
| SCHEMBL6316372 | 0.85 | NTRK1 (0.44) | RAB9AALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | TACR1 4879/4885P2RX1 1995/4885TMPRSS4 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.